Literature DB >> 9602904

Intralesional treatment of cutaneous leishmaniasis with meglumine antimoniate.

N Aste, M Pau, C Ferreli, P Biggio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9602904     DOI： 10.1046/j.1365-2133.1998.02105.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

2.  Resolution of cutaneous leishmaniasis after acute eczema due to intralesional meglumine antimoniate.

Authors:  Erica de Camargo Ferreira e Vasconcellos; Maria Inês Fernandes Pimentel; Cláudia Maria Valete-Rosalino; Maria de Fátima Madeira; Armando de Oliveira Schubach
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2014 Jul-Aug       Impact factor: 1.846

Review 3.  Leishmaniasis in humans: drug or vaccine therapy?

Authors:  Masoud Ghorbani; Ramin Farhoudi
Journal:  Drug Des Devel Ther       Date:  2017-12-22       Impact factor: 4.162

4.  "Cheaper and better": Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia.

Authors:  Daniel Eid Rodríguez; Miguel San Sebastian; Anni-Maria Pulkki-Brännström
Journal:  PLoS Negl Trop Dis       Date:  2019-11-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.